Table 3.
PLM in univariate analysis for patients with SCC in early FIGO stage
| Characteristic | Primary cohort(n = 782) | Validation cohort(n = 407) | |||||
|---|---|---|---|---|---|---|---|
| PLM(-) (%) | PLM(+) (%) | P-value | PLM(-) (%) | PLM(+) (%) | P-value | ||
| Preoperative SCC-Ag | <0.05 | <0.05 | |||||
| ≤3.26 | 514 (77.4) | 47(39.8) | 222 (71.8) | 42 (42.9) | |||
| >3.26 | 150 (22.6) | 71(60.2) | 87 (28.2) | 56 (57.1) | |||
| Age(year) | 0.20 | 0.43 | |||||
| ≤50 | 421 (63.4) | 82(69.5) | 156 (50.5) | 45 (45.9) | |||
| >50 | 243 (36.6) | 36(30.5) | 153 (49.5) | 53 (54.1) | |||
| PLT level (×10^9/L) | <0.05 | 0.26 | |||||
| ≤300 | 568 (85.5) | 92(78.0) | 235(76.1) | 69 (70.4) | |||
| >300 | 96 (14.5) | 26(22.0) | 74(23.9) | 29 (29.6) | |||
| FIGO stage | <0.05 | <0.05 | |||||
| IA-IB | 462 (69.6) | 65(55.1) | 200 (64.7) | 50 (51.0) | |||
| IIA | 202 (30.4) | 53(44.9) | 109 (35.3) | 48 (49.0) | |||
| Grade | 0.80 | 0.79 | |||||
| Good or moderate | 505 (76.1) | 91(77.1) | 242 (78.3) | 78(79.6) | |||
| Poor | 159 (23.9) | 27(22.9) | 67 (21.7) | 20 (20.4) | |||
| PI | <0.05 | <0.05 | |||||
| Negative | 660 (99.4) | 111(94.1) | 300(97.1) | 80 (81.6) | |||
| Positive | 4 (0.6) | 7(5.9) | 9 (2.9) | 18 (18.4) | |||
| LVSI | <0.05 | <0.05 | |||||
| Negative | 634 (95.5) | 97(82.2) | 195 (63.1) | 19 (19.4) | |||
| Positive | 30 (4.5) | 21(17.8) | 114 (36.9) | 79 (80.6) | |||
| DSI | <0.05 | <0.05 | |||||
| ≤2/3 | 446 (67.2) | 53(44.9) | 143 (46.3) | 34 (34.7) | |||
| >2/3 | 218 (32.8) | 65(55.1) | 166(53.7) | 64 (65.3) | |||
| Tumor size | <0.05 | <0.05 | |||||
| ≤4cm | 570 (85.8) | 91(77.1) | 264 (85.4) | 68 (69.4) | |||
| >4cm | 94 (14.2) | 27(22.9) | 45 (14.6) | 30 (30.6) | |||
SCC, squamous cervical cancer; SCC-Ag, squamous cell carcinoma antigen; FIGO, International Federation of Gynecology and Obstetrics; PLT, platelet; PI, parametrial involvement; LVSI, lymphovascular space involvement; DSI, depth of stromal invasion; PLM, pelvic lymphatic metastasis